Hamilton Point Investment Advisors LLC Sells 16,239 Shares of Pfizer Inc. (NYSE:PFE)

Hamilton Point Investment Advisors LLC decreased its stake in Pfizer Inc. (NYSE:PFE) by 9.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 148,165 shares of the biopharmaceutical company’s stock after selling 16,239 shares during the quarter. Hamilton Point Investment Advisors LLC’s holdings in Pfizer were worth $3,931,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of PFE. Coastwise Capital Group LLC grew its holdings in shares of Pfizer by 7.7% in the 4th quarter. Coastwise Capital Group LLC now owns 72,735 shares of the biopharmaceutical company’s stock worth $1,930,000 after purchasing an additional 5,172 shares during the last quarter. CMG Global Holdings LLC increased its holdings in shares of Pfizer by 19.1% during the fourth quarter. CMG Global Holdings LLC now owns 18,277 shares of the biopharmaceutical company’s stock worth $475,000 after buying an additional 2,927 shares in the last quarter. Hartford Financial Management Inc. raised its stake in shares of Pfizer by 8.8% in the fourth quarter. Hartford Financial Management Inc. now owns 6,529 shares of the biopharmaceutical company’s stock valued at $173,000 after acquiring an additional 529 shares during the last quarter. Mine & Arao Wealth Creation & Management LLC. boosted its holdings in shares of Pfizer by 26.2% in the 4th quarter. Mine & Arao Wealth Creation & Management LLC. now owns 8,869 shares of the biopharmaceutical company’s stock worth $235,000 after acquiring an additional 1,844 shares in the last quarter. Finally, Fiduciary Advisors Inc. acquired a new stake in Pfizer during the 4th quarter valued at $70,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Price Performance

Shares of PFE opened at $26.89 on Friday. The stock has a market cap of $152.41 billion, a P/E ratio of 36.34, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The stock’s 50-day moving average price is $26.25 and its two-hundred day moving average price is $27.89. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.17) earnings per share. On average, equities analysts predict that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a $0.43 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.40%. Pfizer’s payout ratio is 232.44%.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on PFE shares. Citigroup reduced their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday. Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Truist Financial dropped their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Bank of America reissued a “neutral” rating and set a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. Finally, Wolfe Research began coverage on shares of Pfizer in a research report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price objective for the company. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.